An Investigation of ReNu™ Knee Injection in Patients With Osteoarthritis

Osteoarthritis Clinical Trial

Official title:

An Investigation of ReNu™ Knee Injection: Monitoring the Response of Knee Function and Pain in Patients With Osteoarthritis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02318511
• Other study ID #: RD2014-10-04
• Status: Completed
• Phase: N/A
• Start date: June 2015
• Est. completion date: February 2019

Study information

• Verified date: January 2020
• Source: NuTech Medical, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Prospective, Randomized study evaluating the efficacy of ReNu for the treatment of Kellgren-Lawrence grade 2 or 3 osteoarthritis. Patients will be randomized into 1 of 3 groups for injection into the effected knee: 1) ReNu - study treatment, 2) Hyaluronic Acid (HA) injection - with commonly used injection material and 3) Saline. After treatment, patients will be followed up to 12 months to evaluate improvements using common pain and function subscales.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: February 2019
• Est. primary completion date: January 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with moderate knee osteoarthritis determined by a combination of clinical and radiographic findings and documented by Kellgren-Lawrence radiographic classification (Grade 2 or 3)

• Grade 2 Kellgren-Lawrence radiographic changes are defined as small osteophytes, possible narrowing of joint space

• Grade 3 Kellgren-Lawrence radiographic changes are defined as moderate multiple osteophytes, definite narrowing of joints space, some sclerosis and possible deformity of bone contour.

• Patients with bilateral grade 2 or 3 Kellgren Lawrence knee osteoarthritis who have bilateral symptoms may have their more symptomatic knee injected. If equivalent symptoms are reported by the patient, then the patient will choose which knee is to be injected. The contralateral knee can be treated with local standard of care such as steroid injection, cold therapy or soft brace.

• Age 18 and older

• BMI less than 40

• 7 day average pain score of 4 or greater for the involved knee on a numeric pain scale from 1 to 10.

• Female patients must be actively practicing a contraception method, abstinence, be surgically sterilized, or be postmenopausal

Exclusion Criteria:

• Pain medication (including nonsteroidal antiinflammatory drugs, NSAIDs) less than 15 days before injection (may take acetaminophen)

• Receiving pain medication other than acetaminophen for conditions unrelated to osteoarthritis of the index knee

• Regular use of anticoagulants, such as Coumadin, dabigatran or rivaroxaban; use of antiplatelet medications are not a reason for exclusion

• History of substance abuse.

• Failure to agree NOT to take additional knee symptom modifying drugs, other than acetaminophen, during the course of the study without reporting to the study team

• Pregnancy or desire to become pregnant during study duration

• Positive pregnancy test on premenopausal subject

• Morbid obesity (defined as BMI 40 or greater)

• Symptoms of locking, intermittent block to range of motion or loose body sensation which could indicate meniscal displacement or an intraarticular loose body

• Corticosteroid injection into the index knee within 3 months

• Viscosupplement injection into the index knee within 3 months

• Knee surgery of involved index knee within 12 months

• Knee surgery contralateral knee 6 months

• Worker compensation

• Acute index knee injury (injury within 3 months)

• History of Diabetes mellitus

• History of solid organ or hematologic transplantation

• History of rheumatoid arthritis or other autoimmune disorder

• Diagnosis of a non-basal cell malignancy within the preceding 5 years

• Infection requiring antibiotic treatment within the preceding 3 months

• Current therapy with any immunosuppressive medication, including corticosteroids at a dose > 5 mg per day

Related Conditions & MeSH terms

• Osteoarthritis

Intervention

Procedure:
• Knee injection
Injection into knee for the treatment of Osteoarthritis

Other:
• ReNu amniotic allograft

Device:
• placebo saline

• Hyaluronic Acid

Locations

Country	Name	City	State
United States	New Mexico Orthopaedics	Albuquerque	New Mexico
United States	American Sports Medicine Institute	Birmingham	Alabama
United States	Brigham and Women's Hospital	Chestnut Hill	Massachusetts
United States	Midwest Orthopedics at Rush, LLC	Chicago	Illinois
United States	Missouri Orthopaedic Institute (MOI)	Columbia	Missouri
United States	The Ohio State University	Columbus	Ohio
United States	Orthoindy	Indianapolis	Indiana
United States	Center for Clinical and Translational Science UK Chandler Medical Center, Pavilion H	Lexington	Kentucky
United States	Cedars-Sinai Medical Center	Los Angeles	California
United States	Hospital for Special Surgery	New York	New York
United States	New York University	New York	New York
United States	Advanced Orthopedics	Richmond	Virginia

Sponsors (2)

Lead Sponsor	Collaborator
NuTech Medical, Inc	Organogenesis

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	VAS Pain Scale Change from Baseline		3 months
Primary	VAS Pain Scale Change from Baseline		6 months
Primary	KOOS Pain and Function Subscales Change from Baseline		3 months
Primary	KOOS Pain and Function Subscales Change from Baseline		6 months
Secondary	KOOS Pain and Function Subscales change from Baseline		1 week, 6 weeks, 3 months, and 12 months
Secondary	Other patient reported outcomes (PROs) change from Baseline		1 week, 6 week, 3 months, 6 months, and 12 months
Secondary	Radiographic (X-ray) measurement of standing joint space change from Baseline		12 months